Efficacy and safety of 4 months of sublingual immunotherapy with recombinant Mal d 1 and Bet v 1 in patients with birch pollen-related apple allergy

SLIT with recombinant Mal d 1 is a promising approach for the effective treatment of birch pollen-related apple allergy.

http://ift.tt/2wuQwCE